Neuroendocrine tumors are rare, accounting for less than 1% of all malignant tumors, and most of them occur in the stomach, intestines, and pancreas. The most common type of cancer in this type of tumor is carcinoid, with an incidence of about 2.5/100000, accounting for 50% of all gastrointestinal pancreatic neuroendocrine tumors. Carcinoid tumors can be divided into anterior intestine (lung, lung, Bronchus and upper gastrointestinal tract up to jejunum), midgut (ileum and appendix) and hindgut (rectum and rectum). Such tumors can occur in the entire neuroendocrine system, but the most common site of involvement is the pancreas. Neuroendocrine tumors can be divided into two major categories according to whether the substances secreted by the tumarara cause typical clinical symptoms mdash; mdash; functional and non-functional.
Parizvino, kurapwa kwakanyanyisa kwematumbo neuroendocrine mupasi peptide receptor radionuclide therapy (PRRT). Iyi inotevera chinyorwa chakanyorwa nachiremba weAmerica pane peptide receptor radionuclide therapy:
Chii chinonzi peptide receptor Radionuclide therapy (PRRT)?
Chii chinonzi peptide receptor radionuclide therapy (PRRT) uye inoshanda sei?
Peptide receptor radionuclide therapy (PRRT) inorapa-inoenderana nemorekuru (inonziwo radioisotope therapy) inoshandiswa kurapa mhando dzekenza, inonzi neuroendocrine malignancies kana tumapundu reNeuroendocrine (neuroendocrine tumors). Peptide receptor radionuclide therapy (PRRT) iri kuongororwawo sekurapa kweprostate uye pancreatic tumors.
Mupeptide receptor radionuclide therapy (PRRT), protein (kana peptide) inonzi cell targeting inonzi octreotide, yakasanganiswa nedikidiki yeradioactive material, kana radionuclide, inogadzira yakakosha mhando yeradiopharmaceutical inonzi radioactive peptide. Kana yaiswa jekiseni muropa remurwere, radioactivity iyi inopinda uye inonamira kune neuroendocrine tumor cell, ichipa yakakwira-dose radiotherapy kune ronda regomarara.
Mune mazhinji neuroendocrine bundu maseru, enrichment (inonzi overexpression) ine huwandu hukuru hwemhando dzakasarudzika dzepasirose receptors - iyi protein inogovaniswa pasero pevhu -hormone yakasungirirwa mumuviri inonzi kukura kwehomoni inhibitory factor. Octreotide ihormone inogadzirwa murabhoritari, inosungirirwa neuroendocrine bundu rekukura kwehomoni inhibitory factor receptor. Mune peptide receptor radionuclide therapy (PRRT), octreotide inosanganiswa nemishonga yekurapa ye radionuclide yttrium-90 (Y-90) uye lutetium 177 (Lu-177) ndiyo inonyanya kushandiswa radionuclide.
Ndezvipi zvirwere zvinogona kurapwa nepeptide receptor radionuclide therapy (PRRT)?
Is peptide receptor radionuclide therapy ( PRRT) used to treat neuroendocrine tumors? (NETs), including carcinoid mamota, pancreatic islet cell carcinoma, small cell lung cancer, pheochromocytoma (a rare tumor formed in the adrenal glands), stomach-intestine-pancreas (stomach, intestine and pancreas) neuroendocrine tumors, And rare thyroid cancer that does not respond to radioactive iodine therapy.
Peptide receptor radionuclide therapy (PRRT) sarudzo yevarwere:
• Murwere akafambira mberi uye / kana akakwira maturo neuroendocrine
• Varwere vasina kukodzera kuvhiyiwa
• Zviratidzo zvemurwere hazviite kune imwe mishonga
Chinangwa chikuru che peptide receptor radionuclide therapy (PRRT) kubatsira kubvisa zviratidzo, kumira kana kunonoka kufambira mberi kwechirwere nekuvandudza kupona kwese.
Inoita sei peptide receptor radionuclide therapy (PRRT) inoshanda?
Zvichienderana nerudzi rwekenza inorapwa uye nemidziyo yekurapa inoitisa nzira yekurapa, varwere vanogona kugamuchira kusvika gumi macircuit ePeptide receptor radionuclide therapy (PRRT), akapatsanurwa mukati memwedzi 10-2. Zvichienderana neiyo radionuclide kurapwa kuri kuitwa nemitemo yemuno, maitiro aya anogona kushandiswa senzira yekurapa yekurapa, kana zvingangoda mazuva mashoma ekurapwa muchipatara.
Yese Peptide receptor radionuclide therapy (PRRT) inotanga kana maamino acids akaiswa jekiseni nyore kudzivirira itsvo dzemurwere kubva kumwaranzi. Iyo radioactive peptide inozoiswa jekiseni mumurwere, ichiteverwa neimwe yekuwedzera amino acid mhinduro. Pakazara, iyo nguva yekurapa yakatora nguva ingangoita maawa mana.
Munguva yekurapa kunotevera, mamorekuru ekufungidzira anogona kuitirwa kucherechedza kuti jekiseni rine radioactive peptide rakapinda sei mumuviri, kunyangwe izvi zvisiri zvekumanikidza.
Ndezvipi zvakanakira peptide receptor radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy (PRRT) uye mamwe marapirwo emamorekuru anogona kupa mamwe ega ega kurapwa kwegomarara nekuti radiopharmaceuticals inogona kugadziridzwa zvichienderana neyakasiyana yehupenyu hwemurwere maitiro uye mamorekuru ebundu. Peptide receptor radionuclide therapy (PRRT) inoonekwawo seyakanangwa kurapa, nekuti radioactive peptides inokwanisa kunyatso paradza neuroendocrine tumor masero, uku ichidzikamisa yakajairika matishu kuratidzwa nemwaranzi. Naizvozvo, kazhinji, peptide receptor radionuclide therapy (PRRT) ine zvinyoro mhedzisiro zvichienzaniswa nechemotherapy.
Peptide receptor radionuclide therapy (PRRT) mhando ine huwandu hwakanyanya hwekubudirira kwesarudzo dzekurapa neuroendocrine bundu rekudzora kwepamberi, kufambira mberi. Peptide receptor radionuclide therapy (PRRT) haisi yekurapa, asi yakaratidzwa kubatsira kubvisa zviratidzo uye kunonoka kukura kwechirwere.
Iko peptide receptor radionuclide therapy (PRRT) yakachengeteka here?
Mishonga yese, kusanganisira peptide receptor radionuclide therapy (PRRT), ine mhedzisiro uye njodzi. Iwe unofanirwa kukurukura nezvengozi uye zvakanakira peptide receptor radionuclide therapy (PRRT) nemupi wako wekurapa, pamwe nechero imwe mishonga yauri kufunga. Kubva pane yako nhoroondo yezvokurapa, wako wekurapa mupi achakubatsira iwe kusarudza kana kwete peptide receptor radionuclide therapy (PRRT) ndiyo yako chaiyo sarudzo chaiyo. Ive neshuwa yekuzivisa mupi wako wekurapa nezve chero kumwe kurapwa kwekutanga kwawakagamuchira, sezvo izvi zvichitora basa rakakosha mukumisikidza kwakaringana kwekurapa uye nemushonga muyero
Side mhedzisiro ye peptide receptor radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy (PRRT) pachayo inonyatsoshivirirwa, asi panguva yeamino acid infusions, varwere vanowanzo kuve nekurutsa uye kurutsa (dzimwe nguva zvakanyanya kwazvo). Izvi zvinoda kurapwa kwekurwisa-kusvotwa kana kudzikisira chiyero cheamino acid manejimendi. Mukufamba kwenguva, mhedzisiro yacho inosanganisira kuwanda kweropa. Pakazara, kurapwa uku kunoregererwa zvakanaka nevarwere vazhinji.
Kuchengetwa kwemusha
Nzvimbo yako yekurapa inokupa rairo yekurapa kunotevera. Nekuti shoma radiotherapy inogona kuramba iri mumuviri, varwere vanofanirwa kurapwa kumwe mushure memazuva 1-2 mushure mekugamuchira peptide receptor radionuclide therapy (PRRT). Nekuti maRadionuclide akasara anobviswa kubva mumuviri kuburikidza neweti netsvina, zvakakosha kuchengetedza hutsanana hwemuzvimbuzi panguva iyi.
Ndezvipi zvitsva zviri kuitika mukutsvaga kwepeptide receptor radionuclide therapy (PRRT)?
Peptide receptor radionuclide therapy (PRRT) tsvagiridzo ikozvino yakatarisana nekupedzisa chikamu chechitatu chekiriniki miedzo, uye inotarisira kugamuchira US FDA mvumo yezviratidziro munguva pfupi ichangotevera. Tsvagiridzo inoenderera mberi inosanganisirawo tsvagiridzo pane izvi zvikumbiro:
• Shandisai peptides maviri pamwechete
• Ma radio peptides akasanganiswa nemimwe mishonga yekurapa
• Yakadzokororwa radiotherapy kunyorera
• Wedzera huwandu hwezviratidzo zverudzi urwu rwekurapa nemwaranzi, kusanganisira zvimwe zvinangwa zvechirwere
• Imwe radionuclide-peptide yekushandisa pamwe.
